Literature DB >> 11160126

Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer.

Y Yamamoto1, R B Gaynor.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11160126      PMCID： PMC199180          DOI： 10.1172/JCI11914

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  47 in total

1.  NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1.

Authors:  D C Guttridge; C Albanese; J Y Reuther; R G Pestell; A S Baldwin
Journal:  Mol Cell Biol       Date:  1999-08       Impact factor: 4.272

2.  Inhibition of NF-kappaB potentiates amyloid beta-mediated neuronal apoptosis.

Authors:  B Kaltschmidt; M Uherek; H Wellmann; B Volk; C Kaltschmidt
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-03       Impact factor: 11.205

3.  NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis.

Authors:  C Y Wang; D C Guttridge; M W Mayo; A S Baldwin
Journal:  Mol Cell Biol       Date:  1999-09       Impact factor: 4.272

Review 4.  Bridging the gap: composition, regulation, and physiological function of the IkappaB kinase complex.

Authors:  E Zandi; M Karin
Journal:  Mol Cell Biol       Date:  1999-07       Impact factor: 4.272

Review 5.  NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses.

Authors:  S Ghosh; M J May; E B Kopp
Journal:  Annu Rev Immunol       Date:  1998       Impact factor: 28.527

6.  Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB.

Authors:  C Y Wang; J C Cusack; R Liu; A S Baldwin
Journal:  Nat Med       Date:  1999-04       Impact factor: 53.440

7.  Suppression of nitric oxide synthase and the down-regulation of the activation of NFkappaB in macrophages by resveratrol.

Authors:  S H Tsai; S Y Lin-Shiau; J K Lin
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

8.  Proteasome inhibitors: a novel class of potent and effective antitumor agents.

Authors:  J Adams; V J Palombella; E A Sausville; J Johnson; A Destree; D D Lazarus; J Maas; C S Pien; S Prakash; P J Elliott
Journal:  Cancer Res       Date:  1999-06-01       Impact factor: 12.701

9.  NF-kappaB function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition.

Authors:  M Hinz; D Krappmann; A Eichten; A Heder; C Scheidereit; M Strauss
Journal:  Mol Cell Biol       Date:  1999-04       Impact factor: 4.272

10.  The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta.

Authors:  M J Yin; Y Yamamoto; R B Gaynor
Journal:  Nature       Date:  1998-11-05       Impact factor: 49.962
View more
  372 in total

Review 1.  NF-kappaB: a key role in inflammatory diseases.

Authors:  P P Tak; G S Firestein
Journal:  J Clin Invest       Date:  2001-01       Impact factor: 14.808

2.  IKKalpha regulates mitogenic signaling through transcriptional induction of cyclin D1 via Tcf.

Authors:  Chris Albanese; Kongming Wu; Mark D'Amico; Christy Jarrett; David Joyce; Julian Hughes; James Hulit; Toshiyuki Sakamaki; Maofu Fu; Avri Ben-Ze'ev; Jacqueline F Bromberg; Carmela Lamberti; Udit Verma; Richard B Gaynor; Stephen W Byers; Richard G Pestell
Journal:  Mol Biol Cell       Date:  2003-02       Impact factor: 4.138

3.  Tyrosine phosphorylation is required for IkappaB kinase-beta (IKKbeta) activation and function in osteoclastogenesis.

Authors:  Isra Darwech; Jesse E Otero; Muhammad A Alhawagri; Yousef Abu-Amer
Journal:  J Biol Chem       Date:  2010-06-09       Impact factor: 5.157

4.  Zyflamend suppresses growth and sensitizes human pancreatic tumors to gemcitabine in an orthotopic mouse model through modulation of multiple targets.

Authors:  Ajaikumar B Kunnumakkara; Bokyung Sung; Jayaraj Ravindran; Parmeswaran Diagaradjane; Amit Deorukhkar; Sanjit Dey; Cemile Koca; Zhimin Tong; Juri G Gelovani; Sushovan Guha; Sunil Krishnan; Bharat B Aggarwal
Journal:  Int J Cancer       Date:  2011-11-09       Impact factor: 7.396

Review 5.  Comparing HMG-CoA reductase inhibitors.

Authors:  Peter H Jones
Journal:  Clin Cardiol       Date:  2003-01       Impact factor: 2.882

Review 6.  Nuclear factor (NF)-kappaB proteins: therapeutic targets.

Authors:  I M Verma
Journal:  Ann Rheum Dis       Date:  2004-11       Impact factor: 19.103

7.  Enzymatic extract from Ecklonia cava induces the activation of lymphocytes by IL-2 production through the classical NF-κB pathway.

Authors:  Ginnae Ahn; Eunjin Park; Won-Woo Lee; Jin-Won Hyun; Ki-Wan Lee; Taekyun Shin; You-Jin Jeon; Youngheun Jee
Journal:  Mar Biotechnol (NY)       Date:  2010-05-18       Impact factor: 3.619

8.  Dietary bioflavonoids inhibit Escherichia coli ATP synthase in a differential manner.

Authors:  Nagababu Chinnam; Prasanna K Dadi; Shahbaaz A Sabri; Mubeen Ahmad; M Anaul Kabir; Zulfiqar Ahmad
Journal:  Int J Biol Macromol       Date:  2010-03-25       Impact factor: 6.953

9.  Drainage of inflammatory macromolecules from the brain to periphery targets the liver for macrophage infiltration.

Authors:  Linlin Yang; Jessica A Jiménez; Alison M Earley; Victoria Hamlin; Victoria Kwon; Cameron T Dixon; Celia E Shiau
Journal:  Elife       Date:  2020-07-31       Impact factor: 8.140

10.  Nuclear factor-kappaB1 (p50) limits the inflammatory and fibrogenic responses to chronic injury.

Authors:  Fiona Oakley; Jelena Mann; Sarah Nailard; David E Smart; Narendra Mungalsingh; Christothea Constandinou; Shakir Ali; Susan J Wilson; Harry Millward-Sadler; John P Iredale; Derek A Mann
Journal:  Am J Pathol       Date:  2005-03       Impact factor: 4.307
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.